0.05Open0.05Pre Close0 Volume95 Open Interest5.00Strike Price0.00Turnover465.75%IV288.46%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1252Delta0.1857Gamma26.00Leverage Ratio-0.0091Theta0.0000Rho3.26Eff Leverage0.0005Vega
Sangamo Therapeutics Stock Discussion
idk
Shortly after close, the $S&P 500 Index (.SPX.US)$ dipped 0.43% to 5,881.63, the $Dow Jones Industrial Average (.DJI.US)$ edged down 0.07% to 42,544.22, and the $Nasdaq Composite Index (.IXIC.US)$ dropped 0.9% to 19,310.79.
For the year, the Nasdaq Composite led the way, rising 29%. The S&P 500 was up 23% (a second straight year of 20% gains) and the Dow added almost 13%.
MACR...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. No buy pressure/momentum- No day t...
Benzinga· 4 mins ago
Sangamo believes that its recently announced partnerships with Genentech and Astellas, and advanced business development discussions for its Fabry gene therapy program, will allow it to chart a path forward for its n...
No comment yet